2018
DOI: 10.1158/1078-0432.ccr-17-3837
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Running title: Somatic genomic landscape of circulating tumor DNA Keywords: circulating tumor DNA, tumor heterogeneity, resistance, genomic landscape, cfDNA clonality Financial support: The study was funded by and conducted at Guardant Health, Inc. No additional grant support or administrative support was provided for the study. *Corresponding author:Stephen R. Fairclough Translational relevanceThis study describes genomic alterations from the largest cell-free circulating tumor DNA cohort to date, as derived… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

11
223
1
2

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 277 publications
(237 citation statements)
references
References 41 publications
11
223
1
2
Order By: Relevance
“…Zill et al . used Guardant360 assay to sequence cfDNA in 21 867 advanced cancer patients including 867 PDAC samples and reported the genomic findings and the response outcomes (Zill et al ., ). Recent progress enabled whole‐genome sequencing to be applied to a liquid biopsy (Dawson et al ., ).…”
Section: Current Technologies In Ctdnamentioning
confidence: 97%
See 1 more Smart Citation
“…Zill et al . used Guardant360 assay to sequence cfDNA in 21 867 advanced cancer patients including 867 PDAC samples and reported the genomic findings and the response outcomes (Zill et al ., ). Recent progress enabled whole‐genome sequencing to be applied to a liquid biopsy (Dawson et al ., ).…”
Section: Current Technologies In Ctdnamentioning
confidence: 97%
“…Platforms such as safe-sequencing system (Safe-SeqS) (Kinde et al, 2011), TAm-Seq (Forshew et al, 2012), Ion-AmpliSeq (Rothe et al, 2014), CAPP-Seq (Newman et al, 2014), and sensitive mutation detection using sequencing (SiMSen-seq) (Stahlberg et al, 2017) have been developed. Zill et al used Guardant360 assay to sequence cfDNA in 21 867 advanced cancer patients including 867 PDAC samples and reported the genomic findings and the response outcomes (Zill et al, 2018). Recent progress enabled whole-genome sequencing to be applied to a liquid biopsy (Dawson et al, 2013).…”
Section: Current Technologies In Ctdnamentioning
confidence: 99%
“…We compared somatic mutations detected in the ctDNA of our study cohort with the identified druggable mutations documented in the National Center for Biotechnology Information ClinVar database and previous reports of tissue sequencing results. 14,15 Analysis of ctDNA of the 17 patients revealed that 7 patients harbored a total of 8 druggable somatic mutations and 1 patient had ERBB2 amplification ( Table 2). The most frequent druggable mutations occurred at two hotspots of the PIK3CA gene.…”
Section: Identifications Of Actionable Genomic Alterations From Ctdnamentioning
confidence: 99%
“…Furthermore, ctDNA opens up the possibility to detect cancer at an early stage as well as to assess tumours which are difficult to biopsy due to location [3]. In a recent large-scale study, investigating 70 defined cancer genes in 21 807 patients with advanced cancers across more than 50 cancer types, somatic alterations were detected in ctDNA in 85% of patients, ranging between 51% and 93% in different tumour types [4]. Based on the findings in this study and others, it is apparent that the feasibility of ctDNA analysis is highly dependent on the type of genomic alterations that are present and relevant to investigate in a particular tumour.…”
Section: Introductionmentioning
confidence: 99%